2023-07-13 00:31:16
Enhance competitiveness in the domestic skin disease treatment market with a diverse product lineup
JW New Drug-Galderma Korea 0JW New Drug recently signed a domestic exclusive sales contract with Galderma Korea for hair loss treatment ‘L-Cranel Alpha Liquid (ingredient name: Alphatradiol)’ and toenail athlete’s foot treatment ‘Loceryl Nail Lacquer (ingredient name Amorolfin)’ has signed Yonggwan Kim<오른쪽> JW Shinyak CEO and Kim Yeon-hee, Galderma Korea CEO, are taking a commemorative photo following signing the contract. /Picture = JW Shinyak JW Shinyak recently signed a domestic exclusive sales contract with Galderma Korea for hair loss treatment ‘L-Cranel Alpha Liquid (ingredient name: Alphatradiol)’ and toenail athlete’s foot treatment ‘Roceryl Nailaca (ingredient name: Amorolfin)’ and began expanding related markets. Accordingly, JW Shinyak will be in charge of domestic sales and marketing of Galderma Korea’s L-Cranel Alpha Liquid and Roseryl Nail Lacquer.
According to the company on the 13th, L-Cranel Alpha Solution is an androgenic alopecia treatment that can be used by both men and women. It minimizes hair loss by suppressing the production of dihydrotestosterone, which is the cause of hair loss, by threefold. In addition, it can be used once a day, and it can be easily applied to the scalp with an applicator, increasing convenience.
Roseryl Nail Lacque is the first product Galderma Korea launched in Korea in 1999, and is the most sold topical treatment for toenail fungus (onychomycosis) in the world. It is a manicure-type external application that is applied directly to the nails, and the antifungal effect is maintained for 7 to 14 days just by using it once or twice a week. It is quickly absorbed into the nail, is not easily erased by water or sweat, and forms a protective film on the surface to prevent infection.
With this contract as an opportunity, JW Shinyak plans to further enhance its competitiveness in the domestic skin disease treatment market. Currently, JW Shinyak supplies eight product groups that can be prescribed according to the cause of hair loss such as genetic, childbirth, and seborrheic dermatitis, such as ‘Monad (ingredient name finasteride)’ and ‘Neodat (ingredient name dutasteride)’, and is reborn as a leader in the hair loss treatment market. there is. In particular, the company emphasized that Monad has been ranked No. 1 in sales of generics in the same class for several years with little side effects from long-term use.
An official from JW Shinyak said, “We have established a diverse lineup with the introduction of Galderma products that have been recognized for their excellence in the global market.
1689210728
#Shinyak #exclusive #supply #global #hair #loss #athletes #foot #treatment #Expansion #clinic #medicines
